

Special Issue

Targeted Radionuclide Diagnosis and Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

Message from the Guest Editor

Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related death. Due to the significant mortality and morbidity rate associated with the progression of this disease, there is an urgent need for the development and application of precise diagnostic imaging agents and effective therapeutic strategies for prostate cancer patients. In recent years, tremendous progress has been made in managing prostate cancer patients, partially due to achievements in radioligand-driven imaging and therapy. This Special Issue welcomes original research articles, communications and review articles dealing with the design, synthesis, and evaluation of new potentially active radiopharmaceuticals for the radionuclide-targeted diagnosis and therapy of prostate cancer. Studies using pre- and clinical data on radiotheranostics and nanoparticle-based radiopharmaceutical applications in prostate cancer diagnosis and therapy, including their safety and efficacy, are also welcome.

Guest Editor

Prof. Dr. Anna Lankoff

1. Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland
2. Department of Medical Biology, Institute of Biology, Jan Kochanowski University, Uniwersytecka 7, 24-406 Kielce, Poland

Deadline for manuscript submissions

closed (31 October 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/108995

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).